These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 3023210)

  • 41. Prostacyclin-thromboxane interactions in the platelet-perfused in vitro heart.
    Schrör K; Köhler P; Müller M; Peskar BA; Rösen P
    Am J Physiol; 1981 Jul; 241(1):H18-25. PubMed ID: 6264810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased platelet arachidonic acid metabolism in diabetes mellitus.
    Halushka PV; Mayfield R; Wohltmann HJ; Rogers RC; Goldberg AK; McCoy SA; Loadholt CB; Colwell JA
    Diabetes; 1981; 30(Suppl 2):44-8. PubMed ID: 6795072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
    Hardee MM; Moore JN; Hardee GE
    Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostaglandins and platelets.
    Mustard JF; Kinlough-Rathbone RL; Packham MA
    Annu Rev Med; 1980; 31():89-96. PubMed ID: 6994628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis--effect of low-dose aspirin.
    Kyrle PA; Minar E; Brenner B; Eichler HG; Heistinger M; Marosi L; Lechner K
    Thromb Haemost; 1989 Jun; 61(3):374-7. PubMed ID: 2508252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostaglandins and platelet aggregation.
    Smith JB
    Acta Med Scand Suppl; 1981; 651():91-9. PubMed ID: 7034481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo.
    Lewis GP; Smith JR
    Prostaglandins; 1984 Jul; 28(1):29-41. PubMed ID: 6435186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Congenital deficiency of thromboxane and prostacyclin.
    Pareti FI; Mannucci PM; D'Angelo A; Smith JB; Sautebin L; Galli G
    Lancet; 1980 Apr; 1(8174):898-901. PubMed ID: 6103258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery.
    Pfister SL
    Hypertension; 2004 Feb; 43(2):428-33. PubMed ID: 14718367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.
    Minkes M; Stanford N; Chi MM; Roth GJ; Raz A; Needleman P; Majerus PW
    J Clin Invest; 1977 Mar; 59(3):449-54. PubMed ID: 190267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heparin inhibits the formation of endoperoxide metabolites in rat platelets: aspirin-like activity.
    Hwang DH; LeBlanc P
    Prostaglandins Med; 1981 Apr; 6(4):341-4. PubMed ID: 7280114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins.
    Giembycz MA; Kroegel C; Barnes PJ
    J Immunol; 1990 May; 144(9):3489-97. PubMed ID: 2158510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-dose aspirin inhibits platelet and venous cyclo-oxygenase in man.
    Preston FE; Greaves M; Jackson CA; Stoddard CJ
    Thromb Res; 1982 Aug; 27(4):477-84. PubMed ID: 6815823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
    Sincholle D; Coquelet C; Bonne C
    Arzneimittelforschung; 1986; 36(1):117-9. PubMed ID: 3082339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of PSK on prostaglandin metabolism (I)].
    Takahata K; Yamanaka M; Oka H
    Gan To Kagaku Ryoho; 1985 May; 12(5):1131-6. PubMed ID: 3888117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.
    Patrono C; Ciabattoni G; Remuzzi G; Gotti E; Bombardieri S; Di Munno O; Tartarelli G; Cinotti GA; Simonetti BM; Pierucci A
    J Clin Invest; 1985 Sep; 76(3):1011-8. PubMed ID: 3900132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man.
    Nowak J; FitzGerald GA
    J Clin Invest; 1989 Feb; 83(2):380-5. PubMed ID: 2643628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro.
    Smith JB; Jubiz W
    Prostaglandins; 1981 Sep; 22(3):353-63. PubMed ID: 7302264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.